NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.65
$0.72
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
91,558 shs
Average Volume
1.73 million shs
Market Capitalization
$2.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RXII stock logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
What is Medicare Supplement Insurance?
Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you.
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
See More Headlines
Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2018
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RXII
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-12,450,000.00
Net Margins
-4,990.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$0.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.94 million
Optionable
Not Optionable
Beta
2.07
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Gerrit Dispersyn
    President, Chief Executive Officer & Director
  • James Cardia
    Vice President-Business Operations
  • Caitlin Kontulis
    Secretary, VP-Finance & Administration
  • Simon Fricker
    Vice President-Research

RXII Stock Analysis - Frequently Asked Questions

How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%.

When did RXi Pharmaceuticals' stock split?

RXi Pharmaceuticals shares reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of RXi Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and

This page (NASDAQ:RXII) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners